미국의 Drug Discovery 아웃소싱 시장 규모, 점유율, 동향 분석 보고서 : 워크플로우별, 약제별, 서비스별, 치료 분야별, 최종 용도별, 부문 예측, 2025년-203년

Market Size & Trends:

The U.S. drug discovery outsourcing market size was estimated at USD 2.49 billion in 2024 and is projected to grow at a CAGR of 9.52% from 2025 to 2033. The market for drug discovery outsourcing is driven by growing demand for novel drug candidates, rising incidence of chronic diseases, increasing R&D expenditures, emerging new private-public partnerships, a need for specialized knowledge, and a growing array of complex and targeted therapies.

Besides, most of the biopharmaceutical and pharmaceutical companies are turning to CROs and CDMOs to leverage advanced technologies such as artificial intelligence, bioinformatics, and high-throughput screening. In addition, the rising number of small and virtual biotech companies, which often lack robust internal capabilities, further accelerates the trend toward outsourcing.

Moreover, shifting trends towards personalized medicine and adaptable development frameworks enhances the demand for outsourced discovery services. Globalization, the need for quicker time-to-IND submissions, and the emergence of new therapeutic areas are continuously driving outsourcing as a key strategy for growth.

In addition, the emergence of personalized medicine is driving the need for adaptable, small-batch production within the U.S. drug discovery outsourcing sector. As treatments become increasingly targeted, particularly in areas like oncology, rare diseases, and gene therapy, traditional mass production methods are shifting towards customized drug development strategies, which are expected to drive the market growth over the estimated time period.

Contract research organizations (CROs) and contract development and research organizations (CDROs) utilize a modular infrastructure, flexible workflows, and quick assay development are becoming vital partners. Outsourcing provides biopharma companies with the ability to navigate variability in drug design, patient stratification, and biomarker-driven studies, which in turn enhances their agility, cost-effectiveness, and speed in bringing precision therapies to market.

Furthermore, the growing integration of artificial intelligence (AI) and machine learning (ML) in drug discovery is transforming the process of identifying, optimizing, and validating compounds. AI streamlines target identification, assesses drug-likeness, and models molecular interactions, leading to significant reductions in early-stage R&D timelines and expenses. Besides, ML algorithms sift through extensive datasets ranging from omics data to clinical outcomes to reveal innovative insights and minimize risks in candidate selection.

In addition, biopharma companies in the U.S. are increasingly incorporating AI-driven solutions into their workflows or collaborating with AI-focused contract research organizations (CROs) to boost productivity, accelerate the path to Investigational New Drug (IND) applications, and enhance success rates in the development of treatments for complex and rare diseases. For instance, in July 2024, Exscientia plc mentioned Amazon Web Services expansion to use the AI & ML services of cloud providers to power the company's platform for end-to-end drug discovery and automation. Such factors are expected to drive the estimated time period.

U.S. Drug Discovery Outsourcing Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. drug discovery outsourcing market report based on workflow, drug, service, therapeutics area, end use, and country.

• Workflow Outlook (Revenue, USD Million, 2021 - 2033)
• Target Identification & Screening
• Target Validation & Functional Informatics
• Lead Identification & Candidate Optimization
• Preclinical Development
• Others
• Drug Outlook (Revenue, USD Million, 2021 - 2033)
• Small Molecules
• Large Molecules
• Service Outlook (Revenue, USD Million, 2021 - 2033)
• Chemistry Services
• Biology Services
• Therapeutics Area Outlook (Revenue, USD Million, 2021 - 2033)
• Respiratory system
• Pain and Anesthesia
• Oncology
• Ophthalmology
• Hematology
• Cardiovascular
• Endocrine
• Gastrointestinal
• Immunomodulation
• Anti-infective
• Central Nervous System
• Dermatology
• Genitourinary System
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Pharmaceutical & Biotechnology companies
• Academic Institutes

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Workflow
  • 1.2.2. Drug
  • 1.2.3. Service
  • 1.2.4. Therapeutics Area
  • 1.2.5. End Use
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information Or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis
  • 1.7.2. Value chain-based analysis
  • 1.7.3. Multivariate Analysis
• 1.8. List of Secondary Sources
• 1.9. List of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Drug Discovery Outsourcing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising R&D cost in biopharmaceutical Industry
    • 3.2.1.2. Increasing access to specialized expertise
    • 3.2.1.3. Growing demand for outsourcing Services in Drug Development
    • 3.2.1.4. Increasing number of partnerships in U.S. Drug Discovery research
    • 3.2.1.5. Technological advancements in drug discovery
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Presence of open-source software packages for drug discovery
    • 3.2.2.2. High manufacturing costs coupled with high risk of drug failure
    • 3.2.2.3. Rising Data Security and IP Concerns
    • 3.2.2.4. Regulatory and Compliance Risks
• 3.3. Clinical Trials Volume Analysis (2024)
  • 3.3.1. Total Number of Clinical Trials, By Region
  • 3.3.2. Total Number of Clinical Trials, By Phase
  • 3.3.3. Total Number of Clinical Trials, By Study Design
  • 3.3.4. Total Number of Clinical Trials, By Key Therapeutic Area
• 3.4. Pricing Model Analysis
• 3.5. Technology Landscape
• 3.6. Market Analysis Tools
  • 3.6.1. Porter's Five Force Analysis
  • 3.6.2. PESTEL by SWOT Analysis
  • 3.6.3. COVID-19 Impact Analysis

Chapter 4. U.S. Drug Discovery Outsourcing Market: Workflow Estimates & Trend Analysis

• 4.1. U.S. Drug Discovery Outsourcing Market, By Workflow: Segment Dashboard
• 4.2. U.S. Drug Discovery Outsourcing Market, By Workflow: Movement Analysis
• 4.3. U.S. Drug Discovery Outsourcing Market Estimates & Forecasts, By Workflow, 2021 - 2033 (USD Million)
• 4.4. Target Identification & Screening
  • 4.4.1. Target Identification & Screening Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Target Validation & Functional Informatics
  • 4.5.1. Target Validation & Functional Informatics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Lead Identification & Candidate Optimization
  • 4.6.1. Lead Identification & Candidate Optimization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.7. Preclinical Development
  • 4.7.1. Preclinical Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.8. Others
  • 4.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Drug Discovery Outsourcing Market: Drug Estimates & Trend Analysis

• 5.1. U.S. Drug Discovery Outsourcing Market, By Drug: Segment Dashboard
• 5.2. U.S. Drug Discovery Outsourcing Market, By Drug: Movement Analysis
• 5.3. U.S. Drug Discovery Outsourcing Market Estimates & Forecasts, By Drug, 2021 - 2033 (USD Million)
• 5.4. Small Molecules
  • 5.4.1. Small Molecules Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Large Molecules
  • 5.5.1. Large Molecules Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Drug Discovery Outsourcing Market: Service Estimates & Trend Analysis

• 6.1. U.S. Drug Discovery Outsourcing Market, By Service: Segment Dashboard
• 6.2. U.S. Drug Discovery Outsourcing Market, By Service: Movement Analysis
• 6.3. U.S. Drug Discovery Outsourcing Market Estimates & Forecasts, By Service, 2021 - 2033 (USD Million)
• 6.4. Chemistry Services
  • 6.4.1. Chemistry Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Biology Services
  • 6.5.1. Biology Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. U.S. Drug Discovery Outsourcing Market: Therapeutics Area Estimates & Trend Analysis

• 7.1. U.S. Drug Discovery Outsourcing Market, By Therapeutics Area: Segment Dashboard
• 7.2. U.S. Drug Discovery Outsourcing Market, By Therapeutics Area: Movement Analysis
• 7.3. U.S. Drug Discovery Outsourcing Market Estimates & Forecasts, By Therapeutics Area, 2021 - 2033 (USD Million)
• 7.4. Respiratory system
  • 7.4.1. Respiratory System Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Pain and Anesthesia
  • 7.5.1. Pain and Anesthesia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Oncology
  • 7.6.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. Ophthalmology
  • 7.7.1. Ophthalmology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.8. Hematology
  • 7.8.1. Hematology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.9. Cardiovascular
  • 7.9.1. Cardiovascular Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.10. Endocrine
  • 7.10.1. Endocrine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.11. Gastrointestinal
  • 7.11.1. Gastrointestinal Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.12. Immunomodulation
  • 7.12.1. Immunomodulation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.13. Anti-infective
  • 7.13.1. Anti-infective Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.14. Central Nervous System
  • 7.14.1. Central Nervous System Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.15. Dermatology
  • 7.15.1. Dermatology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.16. Genitourinary System
  • 7.16.1. Genitourinary System Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. U.S. Drug Discovery Outsourcing Market: End Use Estimates & Trend Analysis

• 8.1. U.S. Drug Discovery Outsourcing Market, By End Use: Segment Dashboard
• 8.2. U.S. Drug Discovery Outsourcing Market, By End Use: Movement Analysis
• 8.3. U.S. Drug Discovery Outsourcing Market Estimates & Forecasts, By End Use, 2021 - 2033 (USD Million)
• 8.4. Pharmaceutical & Biotechnology companies
  • 8.4.1. Pharmaceutical & Biotechnology companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.5. Academic Institutes
  • 8.5.1. Academic Institutes Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Market Participant Categorization
• 9.2. Company Market Share/Assessment Analysis, 2024
• 9.3. Company Profiles
  • 9.3.1. Albany Molecular Research Inc.
    • 9.3.1.1. Company Overview
    • 9.3.1.2. Financial Performance
    • 9.3.1.3. Service Benchmarking
    • 9.3.1.4. Strategic Initiatives
  • 9.3.2. EVOTEC
    • 9.3.2.1. Company Overview
    • 9.3.2.2. Financial Performance
    • 9.3.2.3. Service Benchmarking
    • 9.3.2.4. Strategic Initiatives
  • 9.3.3. Laboratory Corporation of America Holdings
    • 9.3.3.1. Company Overview
    • 9.3.3.2. Financial Performance
    • 9.3.3.3. Service Benchmarking
    • 9.3.3.4. Strategic Initiatives
  • 9.3.4. GenScript
    • 9.3.4.1. Company Overview
    • 9.3.4.2. Financial Performance
    • 9.3.4.3. Service Benchmarking
    • 9.3.4.4. Strategic Initiatives
  • 9.3.5. Pharmaceutical Product Development, LLC
    • 9.3.5.1. Company Overview
    • 9.3.5.2. Financial Performance
    • 9.3.5.3. Service Benchmarking
    • 9.3.5.4. Strategic Initiatives
  • 9.3.6. Charles River Laboratories
    • 9.3.6.1. Company Overview
    • 9.3.6.2. Financial Performance
    • 9.3.6.3. Service Benchmarking
    • 9.3.6.4. Strategic Initiatives
  • 9.3.7. WuXi AppTec
    • 9.3.7.1. Company Overview
    • 9.3.7.2. Financial Performance
    • 9.3.7.3. Service Benchmarking
    • 9.3.7.4. Strategic Initiatives
  • 9.3.8. Thermo Fisher Scientific Inc.
    • 9.3.8.1. Company Overview
    • 9.3.8.2. Financial Performance
    • 9.3.8.3. Service Benchmarking
    • 9.3.8.4. Strategic Initiatives
  • 9.3.9. Dalton Pharma Services
    • 9.3.9.1. Company Overview
    • 9.3.9.2. Financial Performance
    • 9.3.9.3. Service Benchmarking
    • 9.3.9.4. Strategic Initiatives
  • 9.3.10. Oncodesign
    • 9.3.10.1. Company Overview
    • 9.3.10.2. Financial Performance
    • 9.3.10.3. Service Benchmarking
    • 9.3.10.4. Strategic Initiatives
  • 9.3.11. Jubilant Biosys
    • 9.3.11.1. Company Overview
    • 9.3.11.2. Financial Performance
    • 9.3.11.3. Service Benchmarking
    • 9.3.11.4. Strategic Initiatives
  • 9.3.12. DiscoverX Corp.
    • 9.3.12.1. Company Overview
    • 9.3.12.2. Financial Performance
    • 9.3.12.3. Service Benchmarking
    • 9.3.12.4. Strategic Initiatives
  • 9.3.13. QIAGEN
    • 9.3.13.1. Company Overview
    • 9.3.13.2. Financial Performance
    • 9.3.13.3. Service Benchmarking
    • 9.3.13.4. Strategic Initiatives
  • 9.3.14. Eurofins SE
    • 9.3.14.1. Company Overview
    • 9.3.14.2. Financial Performance
    • 9.3.14.3. Service Benchmarking
    • 9.3.14.4. Strategic Initiatives
  • 9.3.15. Syngene International Limited
    • 9.3.15.1. Company Overview
    • 9.3.15.2. Financial Performance
    • 9.3.15.3. Service Benchmarking
    • 9.3.15.4. Strategic Initiatives
  • 9.3.16. Dr. Reddy Laboratories Ltd.
    • 9.3.16.1. Company Overview
    • 9.3.16.2. Financial Performance
    • 9.3.16.3. Service Benchmarking
    • 9.3.16.4. Strategic Initiatives
  • 9.3.17. Pharmaron Beijing Co., Ltd.
    • 9.3.17.1. Company Overview
    • 9.3.17.2. Financial Performance
    • 9.3.17.3. Service Benchmarking
    • 9.3.17.4. Strategic Initiatives
  • 9.3.18. TCG Lifesciences Pvt Ltd.
    • 9.3.18.1. Company Overview
    • 9.3.18.2. Financial Performance
    • 9.3.18.3. Service Benchmarking
    • 9.3.18.4. Strategic Initiatives
  • 9.3.19. Domainex Ltd.
    • 9.3.19.1. Company Overview
    • 9.3.19.2. Financial Performance
    • 9.3.19.3. Service Benchmarking
    • 9.3.19.4. Strategic Initiatives

Chapter 10. Key Recommendations